Abstract: In the search of new strategies to improve the quality of life of Parkinson's disease patients, recent work has reported an amelioration of Parkinsonian symptoms using Whole Body Vibration (WBV). A double-blinded, placebo controlled design was used to evaluate the effect of a 12 WBV sessions-programme on a number of motor and clinical tests in 23 Parkinson's disease patients. Patients were assigned to one of two groups, one receiving WBV and the other a placebo group. At the end of the programme as well as during intra-session evaluation, there was no difference between the experimental (vibration) and placebo groups in any outcomes. These results suggest that reported benefits of vibration are due to a placebo response.
The use of vibrating platforms has been introduced in the sports medicine aiming to improve strength in disciplines requiring powerful muscle contractions, though its effectiveness has not yet been clearly demonstrated. 1 Recently, this technique has been used in Parkinson's disease patients, with some promising results. [2] [3] [4] Haas et al. 3 have reported an improvement UPDRS scores (rigidity and tremor) in a group of patients after undergoing a single session of whole body vibration (WBV). Previous reports by the same group, 2 showed a significant improvement in postural stability on an unstable platform after one session of WBV. Both studies were performed by applying five sets of 60 seconds each, at 6 Hz, employing stochastic vibration which was one of the key features advocated by the authors. 5 However, more recently, significant effects on Parkinsonian patients have been reported using nonstochastic vibration. 4 These authors showed the effect of 25 Hz stimulation (twice per day, 15 min./each) for 3 weeks which produced an improvement in a set of motor tests (Tinetti balance score, 6 gait velocity, stand-walk-sit test, UPDRS III ), although similar results were seen with conventional rehabilitation therapy (relaxation, occupational therapy, etc.). However, the results by Ebersbach et al. 4 seem important, since, besides the acute effects reported previously, 2,3 they appeared to show long lasting effects. Improvement after the end of the 3 week programme lasted at least 4 more weeks. Nevertheless, as stated by the authors, 2-4 the lack of a control (placebo) is a weakness of these studies. The effect of placebo on different pathologic conditions is well know, and it seems Parkinsonian patients are especially affected, 7, 8 chiefly when a reward is expected (improvement in clinical symptoms due to a new treatment, for instance).
This study aims to evaluate the effect of WBV on motor symptoms on Parkinson's disease patients, while controlling for the placebo effect.
METHODS

Patients
A total of 29 Parkinson's disease patients, belonging to Asociacio´n Parkinson Bueu in Spain were recruited for the study. To take part in the study, patients had to match the primary diagnosis of Parkinson's disease (PD) (based on medical records following established diagnostic criteria); lack of dementia (MMSE 24); lack of artromuscular deficit or joint prosthesis; and be able to cope with OFF periods (n 5 23). Patients were required to complete all sessions and could not change their regime of medication throughout the study. Patients were allocated to either experimental or placebo group based upon an ABBA (A5experimental; B5placebo) distribution model, using their times to complete the Gait test. Although initial allocations placed 12 patients in the experimental group and 11 in the placebo group, which were not significantly different in any pretest measure, 2 patients withdrew from the study. Pretest data for the remaining 10 experimental and 11 placebo patients were still not significantly different (P > 0.05), neither their weight, height, trochanteral height, and acromion-finger length (Table 1) .
Procedure Stimulation
The experimental group received 12 stimulation sessions over 5 weeks, on nonconsecutive days. Based on previous studies reporting beneficial effects on Parkinsonian symptoms 2,3 the stimulation frequency was set at 6 Hz., and each patient underwent 5 sets of stimulation of 1 min each, with an interset rest period of 1 min. During stimulation patients were asked to stand on the vibrating platform, with their feet separated at a stable and comfortable position, and with the knees slightly bent.
For the placebo condition patients adopted the same position but vibration was not applied. Instead placebo patients were required to try to stay as still as they could, trying to minimize hip oscillation, yielding the same amount of weight of both feet.
All other physical therapies usually undergone by the patients were cancelled during the duration of this study. Patients took their medication as usual, and stimulation session started 30-45 min after dose intake (when patients confirmed ON-periods).
Evaluation
We assessed the effect of vibration through two different sets of tests, one to test the effectiveness of the whole programme, and other measuring the acute effect of the different sessions (intra-session evaluation), see Table 2 .
Evaluation of the Effect of the Programme. Evaluation was carried out twice, two days before beginning and 2 days after the end of the intervention period respectively. PD patients were evaluated during their OFF-periods (>12 hr withholding medication); the tests performed were the following: Gait, Pegboard, Intra-Session Evaluation. In addition to the comparisons made before and after the programme, we performed a series of intra-session evaluations, to know the acute effect of stimulation, so that a number of tests (see Table 2 ) were carried out just before and after stimulation. The Timed-up-and-go test (TUG) , and the FR were tested every day. Hand dexterity (Pegboard) were performed at the first, sixth and last stimulation session. For intra-session evaluation patients were evaluated during ON-periods.
All evaluations were performed by researchers blind to protocol and group assignment.
Evaluation Tests. Gait: Subjects had to walk along a corridor, turn (U turn), and come back (see Fig. 1a ); subjects performed this task three times, with a rest of 2 min. The instruction given was ''walk along the corridor as you normally do, turn around the object at the end of the corridor, come back and touch this button on the wall.'' Functional Reach: Subjects had to displace the stick attached to the anthropometer as far as they could, pushing with their fist, without bending the knees or lifting the heels (Fig. 1b,c) . Each subject did so three times for each arm, with a rest of 30 S between trails. The distance between the initial and the final position was taken as the functional reaching distance.
Berg Balance Test: Briefly, the BBT 9 is a 14-item scale widely used for assessing balance. The items are scored from 0 to 4 on the basis of the ability to complete a task, the higher the score the more independently performed the tasks.
UPDRS: The total score and the motor section of the scale were taking into account.
Purdue Pegboard Test: This was used to test hand dexterity-subjects had to place as many pegs (small steel rods) as possible, sequentially into a row of holes, within 30 S, and the number of pegs were registered. Subjects performed this task three times for each hand.
PDQ-39: PDQ-39
10 measures quality of life in Parkinsonian patients. It has 39 items to be rated (0-4), the higher the score the poorer quality of life.
Timed up and go test: Briefly, for the TUG, patients are seated on a chair and once commanded, they had to stand up, walk at their preferred walking pattern for 3 m, turn, come back, and sit down on the chair again. 11 The time taken was recorded with a stopwatch. Patients performed this task three times.
Subjects gave their informed consent to the experimental procedure, conformed to the standards set by the Declaration of Helsinki. Procedure was approved by the University of A Coruñ a Ethics Committee.
Apparatus. For gait evaluation recording system consisted of a series of footswitches worn as insoles in the shoes. The footswitches were connected to a radiotransmitter attached to the subjects' belt. Data (sampled at 1 KHz.) were sent to a receiver unit connected to the computer. This configuration allowed the stride cycle time to be registered. Two photocells, placed 4.50 m apart, were connected to the recording system. For the FR test an Harpenden Anthropometer (Holtain Ltd), calibrated to the nearest millimetre, was mounted on a tripod (see Fig. 1b,c) , so that the functional reaching distance could be obtain from the difference between the starting and the end positions of the moveable part of the anthropometer.
For WBV stimulation was provided by means of a vibrating platform (Fit Massage, PYC Fitness International Inc), commercially available in various countries. The vibrating platform, configurable in frequency (up to 50 hz with an amplitude of 13 mm, model specifications), thrusts the right and left leg upward alternately (in concordance to previous studies, Ebersbach et al. 4 ). Analyzed Variables. For the gait test, a number of kinematic variables were analyzed: -Velocity, it was calculated from the time consumed to cover the straight part of the task, data obtained from the photocells. -Cadence, it was calculated from data obtained through footswitches, corresponding to the straight part of the task. -Step amplitude, derived from the combination of velocity and cadence. -Turn time, obtained from the successive activation of the photocell at the end of the corridor (before and after the turn). -The CV stride-time , obtained from the footswitches data of the straight section, it was define defined as CVð%Þ ¼ ðsd=meanÞ 3 100
All the gait variables correspond to the mean of the tree trials.
For the FR test, it was calculated the mean functional reaching distance obtained in the three trials. Scores from both arms were averaged.
The scores from the BBT, PDQ-39 and UPDRS were introduced in the analysis.
The mean number of pegs introduced into the holes in the three trials was the variable analyzed in the Purdue Pegboard test. Scores from both hands were averaged.
The time consumed to complete the test was the variable analyzed in the TUG test (average from the three trials).
Statistical Analysis
To calculate differences between groups at the pretest a Students "t" for independent samples was applied for each variable. To measure the effect of the whole intervention programme a 2 3 2 ANOVA with repeated measures was performed for each of the variables analyzed Preprogramme vs. Postprogramme. The within subjects factor was Evaluation, with two levels (Pretest and Post-test); the between subjects factor was the Group (experimental or placebo). To know the intra-session effect a three-way ANOVA with repeated measures was performed. For TUG two within-subjects factor were defined, factor Session with 12 levels (each of the sessions), and factor Pre-Post with 2 levels (intra-session evaluation, prestimulation and poststimulation); the between subjects factor was the Group (experimental or placebo). The same model was applied for the FR. For the Pegboard the model was the same as well, but factor Session had just 3 levels (1st, 6th, and 12th sessions).
Normality of distribution was check by K-S test. Greenhouse-Geisser correction was applied when sphericity was violated. The SPSS package was used for statistical analysis.
RESULTS
Preprogramme vs. Postprogramme Characterization
Before stimulation groups were equal in all the variables analyzed (see Table 3 ); for gait variables Students ''t'' for independent sample yielded no significant differences for any of the kinematics: velocity (t(19) 5 0.139 P 5 0.891), cadence (t(19) 5 0.034 P 5 0.974), step amplitude (t(19) 5 0.233 P 5 0.819), turn time (t(19) 5 0.350 P 5 0.730), and CV stride-time (t(19) 5 0.067 P 5 0.948). Also, the rest of the variables showed no differences between groups: UPDRS (t(19) 5 1.466 P 5 0.159); UPDRS III (t(19) 5 1.826 P 5 0.084); BBT (t(19) 5 1.030 P 5 0.316); number of pegs (t(19) 5 0.557 P 5 0.584); FR distance (t(19) 5 0.435 P 5 0.668) and PDQ39 (t(19) 5 0.107 P 5 0.916).
Effect of the Stimulation
A main effect of factor Evaluation was seen in a number of variables, showing significant change between Pre-and Post-test (Table 4 ). In the gait variables this was seen in the following: velocity [F(1,19) For the rest of the tests, the effect of the programme led FR to increase [F(1,19) 5 65.229 P 0.001]; as well as to increase the number of pegs in the Pegboard test [F(1,19) 5 25.617 P 0.001]; to reduce the total UPDRS score and the UPDRS III score [F(1,19) 5 32.903 P 0.001 and F(1,19) 5 11.929 P 5 0.003 respectively) and to reduce the BBT score (F(1,19) 5 22.052 P 0.001). PDQ-39 was not affected by the treatment (F(1,19) 5 2.332 P 5 0.143).
However, the main outcome of this study is provided by the interaction Evaluation*Group-at this level no significant interaction was seen, showing the effect of treatment affected both groups equally. This occurred in all but one of the variables analyzed: velocity (F(1,19) 5 1.648 P 5 0.215; cadence (F(1,19) 5 0.220 P 5 0.644); amplitude (F(1,19) 5 1.447 P 5 0.244); CV stride-time (F(1,19) 
Intra-session Evaluations
The analysis of intra-sessions evaluation yielded similar results to the Preprogramme vs. Postprogramme analysis, even although the medication regime was different, OFF during Preprogramme vs. Postprogramme (except for PDQ-39), and ON during intra-sessions. 
Characterization
Before the first stimulation session, both groups were comparable, as no significant differences were seen at any of the variables analyzed when compared by groups.
For TUG t(19) 5 1.100 & P 5 0.285; for the Pegboard t(19) 5 0.243 & P 5 0.810; and for the FR t(19)50.106 & P 5 0.917 (see Table 3 ).
Stimulation
Stimulation produced interesting results. For the TUG a main effect of factor Session, F(2.765,52.529) 5 5.389 & P 5 0.003, showed patients changed their performance during successive days; however, the lack of interaction of Session*Group (F(2.765,52.529) 5 1.091 P 5 0.358) showed this effect was also seen in both groups, experimental and placebo, ruling out an effect of vibration on motor execution. Similarly, patients performed differently when we compared the execution before and after stimulation as factor PrePost showed a main effect F(1,19) 5 5.758 & P 5 0.027, but again this was seen in both groups of patients (experimental and placebo) as interaction between them was not significant (F(1,19) 5 0.018 P 5 0.894). The rest of the interactions were not significant (Fig. 2) .
For the Pegboard the only factor to have a main effect was factor Pre-Post F(1,19) 5 18.100 P 0.001, however, this again happened for both groups, with the interaction Pre-Post*Group not significant (F(1,19) 5 0.807 P 5 0.380) (Fig. 2) .
Finally, for the FR, the ANOVA showed the reaching distance was affected by the different sessions (factor Session) F(4.896,93.027) 5 23.873 P 0.001. Also factor Pre-Post had a main effect F(1,19) 5 47.727 P 0.001, proving a different performance before or after the course of stimulation; this was also seen between the different sessions as the interaction Session*Pre-Post was also significant (F(11,209) 5 2.058 P 5 0.025). However, the interaction Session*Pre-Post*Group was not significant, proving all changes in performance occurred in both groups (F(11,209) 5 1.310 P 5 0.221) (Fig. 2) . Factor group was not significant at any variable; F(1,19) 5 0.650 P 5 0.430 for TUG; F(1,19) 5 0.041 P 5 0.841 for the Pegboard; and F(1,19) 5 0.235 P 5 0.633 for the FR.
